Allan Shaw currently leads Alvarez & Marsal's biopharmaceutical consulting practice and served as a member of the Board of Directors for the Central New York Biotech Accelerator (formerly Central New York-Biotech Research Center).. Previously, he worked as Chief Financial Officer and executive management board member of Serono. International S.A., a global biotechnology company and the largest in Europe.. He was also the founder and Senior Managing Director of Shaw Strategic Capital LLC, an international financial advisory firm, focused on providing strategic financial counsel on a wide variety of issues such as general corporate finance, mergers and acquisitions, capital structuring, licensing and capital markets.. His clients included a biopharmaceutical licensing / developmental group and an international investment bank, for which he served as a strategic adviser.. Mr. Shaw has served as a Board member and Chief Financial Officer for NewLead Holdings LTD (NASDAQ:NEWL), as well as an independent board member of Navios Maritime Holdings Inc.'s (NYSE: NM), serving as Chairman for Navios' Audit (designated financial expert) and Compensation Committees.. He has contributed to several corporate governance books and is a member of the American Institute of Certified Public Accountants, New York Society of Certified Public Accountants and Corporate Directors Group.. Mr. Shaw graduated with a Bachelor of Science from the State University of New York (Oswego College), and is a certified public accountant in the State of New York. Mr. Shaw is chair of the Audit committee.
